tiprankstipranks
TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
US Market
RNAZ
TransCode Therapeutics
RESEARCH TOOLSreports
Want to see RNAZ full AI Analyst Report?

TransCode Therapeutics (RNAZ) Income Statement

439 Followers

TransCode Therapeutics Income Statement

Last quarter (Q4 2025), TransCode Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, TransCode Therapeutics's net income was $-13.44M. See TransCode Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Mar 24Dec 22Mar 22
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ -534.86K$ -516.75K$ -98.61K$ -42.47K
Operating Expenses
$ 27.98M$ 15.13M$ 18.90M$ 18.57M$ 6.11M
Depreciation and Amortization
$ 114.18K$ 534.86K$ 516.75K$ 98.61K$ 42.47K
EBITDA
$ -34.31M$ -16.19M$ -17.97M$ -17.47M$ -6.71M
Operating Income
$ -27.98M$ -15.66M$ -19.42M$ -18.67M$ -6.15M
Other Income/Expenses
$ -6.45M$ -1.09M$ 872.42K$ 1.10M$ -692.26K
Pretax Income
$ -34.44M$ -16.75M$ -18.55M$ -17.56M$ -6.84M
Net Income
$ -34.66M$ -16.75M$ -18.55M$ -17.56M$ -6.84M
Per Share Metrics
Basic EPS
$ -52.59$ -47.14$ -3.45K$ -73.19K$ -648.00
Diluted EPS
$ -52.59$ -47.14$ -3.45K$ -1.08K$ -648.00
Weighted Average Shares Outstanding
 689.71K 356.12K- 16.22K 10.53K
Weighted Average Shares Outstanding (Diluted)
 689.71K 356.12K- 16.22K 10.53K
Currency in USD

TransCode Therapeutics Earnings and Revenue History